SynthesisThe Lancet. Oncology2016

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Claire L Vale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.